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Abstract
Background: Excessive protocol violations (PV), which can be defined as preventable mistakes in study conduct,
may result in patient harm and introduce errors into a clinical trial’s results leading to flawed trial conclusions.
The purpose of this project was to gain a better understanding of reported PVs, to describe current practice with
regards to the use of methods for the reduction of PVs and to investigate relationships between clinical trial
characteristics and PVs.
Methods: We reviewed 80 clinical trials conducted across a broad range of medical specialties published in four
major general medical journals (The Lancet, NEJM, JAMA, BMJ). Eligible papers were identified using a PubMed
search. For each included trial, two authors independently abstracted information on trial characteristics, PV
reporting and PV rates and interventions used to reduce PVs. PVs were categorised into one of five distinct types:
enrolment, randomisation, study intervention, patient compliance and data collection errors. Associations between
PVs and study characteristics were investigated using logistic regression.
Results: Eighty clinical trials (20 from each journal) were identified from 101 consecutive PubMed abstracts. The
median number of participants was 701 (range: 20 to 162, 367) and the median number of participating sites was 15
(range: 1 to 701). Nineteen percent (15/80) of included trials were single centre trials. The median study duration was
24 months (range: 5.81 - 127 months) and 74% (59/80) of included trials were primarily academic funded.
Thirty two percent (26/80) of included trials failed to provide explicit reporting of any type of PV and none (0/80) of the
trials provided explicit reporting of all five types of PVs. Larger clinical trials (more patients, more sites, longer duration,
more complex management structure) were more likely to have more complete reporting of PV’s.
Only 9% (7/80) of trials reported the use of a specific study method to prevent PVs. Use of a run-in phase was the
only method reported.
Conclusions: PVs are under-reported. Although the CONSORT statement provides guidance on the reporting of
PVs, reporting requirements are not explicit for all types of PVs. As a first step towards improved reporting by
authors, we recommend the CONSORT statement highlight the importance of PVs by making reporting
requirements more explicit.
Keywords: Clinical trials, methods, methodology, protocol violations, protocol deviations, errors of conduct, report-
ing artifact, randomized, randomised
Background
Preventable errors in study conduct, also known as pro-
tocol violations (PV), may lead to the introduction of
bias (systematic errors), play of chance (random errors),
and design errors into a clinical trial that ultimately
results in flawed conclusions [1]. For example, poor
study conduct leading to errors in study treatment dos-
ing may cause harm to enrolled patients [2]. Avoidable
harm arising from incorrect dose calculations will dilute
any true treatment benefits thus reducing overall statis-
tical power leading to a false negative result [1,3]. An
understanding of PV rates may therefore enhance the
interpretation of a clinical trial’s results. * Correspondence: gdoig@med.usyd.edu.au
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appropriate thresholds for acceptable and excessive PV
rates. One authority on the conduct of clinical trials has
suggested that PVs in more than 10% of enrolled
patients is excessive and “reflect[s] a generally poor
standard of trial organisation which needs tightening
up” [3]. Post hoc evaluation committees analysing com-
pleted Food and Drug Administration (FDA) Phase III
licensing trials have reported PVs ranging from 15.6%
(88/564) [4] to 24.9% (431/1728) [2,5] of all enrolled
patients, however neither committee classified these
levels as excessive. We conducted an extensive literature
search [6] to identify publications on this topic.
Although we could find no reviews providing overall
estimates of PV rates, much has been written about
interventions for reducing PVs [1-3,6].
Studies have been conducted to demonstrate that differ-
ent types of PVs can be prevented by using certain study
interventions or design features. For instance, a study run-
in phase c a nb eu s e dt oi d e n t i f yp a t i e n t sf o rs u b s e q u e n t
enrolment who are more likely to be compliant with study
interventions, resulting in improved power due to reduced
study treatment related PVs [7]. A study run-in phase also
provides a protected learning environment such that
researchers can become more familiar with study pro-
cesses and procedures, leading to a reduction in other
types of PVs such as enrolment errors [6]. Furthermore,
enhanced educational interventions such as web based
tutorials that provide feedback throughout the conduct of
a trial can reduce data collection related PVs and study
intervention PVs [1]. Despite the availability of methods
proven to enhance trial conduct, we are uncertain as to
how many trialists actually embrace these methods.
The purpose of this project was to gain a better
understanding of reported PV rates, to describe current
practice with regards to the use of methods for the
reduction of PVs and to investigate relationships
between clinical trial characteristics and PV rates. To
achieve these goals we reviewed 80 consecutive clinical
trials published in four major journals.
Methods
Primary Literature Search
To detect eligible clinical trials for this review we searched
the Lancet, the New England Journal of Medicine, the
Journal of the American Medical Association and the Brit-
ish Medical Journal using the National Library of Medi-
cine’ss e a r c he n g i n ePubMed http://www.PubMed.org.
Phrases optimized to detect randomised controlled trials
(RCTs) [8] were crossed with Medical Subject Heading
(MeSH) Journal Titles. A complete list of the MeSH Jour-
nal Title searches is presented in Table 1.
Consecutive clinical trials published after May 1
st 2009
were retrieved.
Study Selection
All identified abstracts were independently reviewed by
both authors (EAS, GSD). The authors were not blinded
to publication source or abstract author list. Any
abstract that either author believed constituted a clinical
trial was retrieved in full text for detailed review.
Primary publications of cluster randomised and indivi-
dual patient randomised trials, evaluating any type of
intervention (education, drug treatment, surgery etc)
were eligible for inclusion. Publications of subgroup
analyses or economic analyses from previously published
trials were not eligible.
Trial Characteristics
For each included clinical trial, the following trial char-
acteristics were independently appraised and extracted
by both authors (EAS, GSD): study type (individual
patient randomised, cluster randomised or factorial
design); total number of study arms; patient population
(adults, children or infants); study intervention (drug,
surgery, education, other);n u m b e ro fp a t i e n t sr a n d o -
mised; number of study sites; funding source for trial
(primarily academic, primarily commercial); reporting of
trial education/start-up processes; response to protocol
violations; trial results (positive, neutral or harm);
reporting of adherence to Good Clinical Practice (GCP)
recommendations; lead investigator previous experience
with research in the field (previous on topic clinical trial
or observational study reported in reference list); risk of
bias [9] including reporting of randomisation, blinding
and, allocation concealment and; management structure
(type of management structure e.g. management com-
mittee, steering committee etc.). PV rates and specific
methods used to reduce or prevent future PVs were also
abstracted from each paper.
Disagreements between the authors regarding study
inclusion or appraisal were resolved by discussion.
Types of Protocol Violations
Wolf and Makuch define a PV as a departure from the
guidelines specified in the study protocol that could
have been prevented by the investigator [10]. Under
Table 1 Journal name search terms used in primary
MEDLINE search
Journal Medical Subject Heading Terms
The Lancet ("Lancet"[Journal] OR “lancet"[All Fields])
New England Journal of
Medicine
“N Engl J Med"[Journal]
Journal of the American
Medical Association
("JAMA"[Journal] OR “jama"[All Fields])
British Medical Journal ("Br Med J"[Journal] OR “Br Med J (Clin
Res Ed)"[Journal] OR “BMJ"[Journal] OR
“bmj"[All Fields])
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from the study protocol is referred to as a protocol
deviation. For example, discontinuation of the study
intervention due to an unforeseen adverse event or an
act of nature (Ex. Hurricane Katrina) would be classified
a protocol deviation, not a PV. For the purposes of this
study, we did not consider any departure from the study
protocol to be a PV if the departure was considered
necessary to protect the safety of a patient.
We identified and reported on five distinct types of
PVs:
1) Enrolment PVs occurred when a member of the
research team failed to appropriately apply the
study’s eligibility criteria resulting in the enrolment
of an inappropriate patient into the trial.
2) A randomisation PV was defined as a technical
or human error leading to the violation of the
intended randomisation sequence or any attempts to
subvert allocation concealment.
3) A study intervention PV was defined as a dosing,
timing or delivery error in the study intervention
attributable to members of the research team. The
research team included members of the study coor-
dinating centre, site investigators, research coordina-
tors and members of the healthcare team caring for
participants.
4) A patient compliance PV involved study partici-
pants failing to comply with the trial protocol
regarding a study intervention or other requirements
of participation in the trial (e.g. skipping scheduled
appointments). Formal withdrawal of consent to par-
ticipate was not considered a patient compliance PV.
5) Data collection PVs encompassed errors in
which the research team failed to comply with pre-
specific trial guidelines for data collection and/or
outcome evaluation due to avoidable reasons.
The reporting of each type of PV was further
described as explicit, incomplete or absent. Explicit
reporting allowed complete categorisation of the PV by
type and cause. Reporting of cause and type allowed the
determination of whether the departure from protocol
was preventable or safety related.
Analysis
The frequency of occurrence of PVs is reported by type
of PV, calculated as number of PVs divided by number
of enrolled patients. Proportions were only calculated
when PV reporting was explicit. If PVs were not
reported, we did not infer that the PV rate was zero.
Relationships between study characteristics and PVs
were investigated using chi-square tests, t-tests or logis-
tic regression, depending on the independent variable. A
two-tailed P-value less than 0.05 was accepted to
demonstrate the presence of statistical significance.
Results
Primary Literature Search and Study Selection
Hand searching of identified abstracts resulted in the
retrieval of 101 full text papers for detailed review. Eighty
clinical trials, 20 consecutive trials from each major jour-
nal, were identified from these 101 retrieved papers. Rea-
sons for exclusion of 21 papers included: the paper was a
subgroup or economic analysis of a previously published
clinical trial (6); the paper was not a clinical trial (4); the
paper was not published in the target journal (4); sys-
tematic reviews (2) or; other reasons (5).
Trial Characteristics and Risk of Bias
The median number of participants in the included clin-
ical trials was 701 (range: 20 to 162, 367) and the med-
ian number of participating sites was 15 (range: 1 to
701). Nineteen percent (15/80) of included trials were
single centre studies. The median study duration was 24
months (range: 5.81 - 127 months) and 74% (59/80) of
included trials were primarily academic funded. Sixty
five percent (52/80) of the trials reported a significant
positive treatment effect, 32% (26/80) had neutral (nega-
tive) findings and 2.5% (2/80) reported significant harm.
Complete characteristics of the included trials can be
found in Table 2. Risk of bias is reported in Table 3.
Protocol Violation Reporting
Thirty-two percent (26/80) of included trials failed to pro-
vide explicit reporting of any type of PV. None (0/80) of
the trials provided explicit reporting of all five types of PVs.
Explicit reporting varied widely according to PV type,
with explicit reporting highest for patient compliance
PVs (47.5%, 38/80 trials) and lowest for randomisation
PVs (8.75%, 7/80 trials). Table 4 provides complete
reporting details for all types of PVs.
Proportion of Enrolled Participants with Protocol
Violations
Of the 38 trials with explicit reporting of patient com-
pliance PVs, the median proportion of patients with
compliance PVs was 7% (range 0.2% to 87%) of all
enrolled patients. Thus, actual compliance was 93%
(range: 13% to 99.8%). Table 4 reports PV occurrence
by type, abstracted from trials with explicit reporting.
Reporting of methods used to reduce or prevent PVs
Only 9% (7/80) of included trials reported any details
regarding study start-up/site initiation meetings or other
forms of educational training of the research team. Nine
percent (7/80) trials reported the use of a run-in phase.
No other methods were mentioned.
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Enrolment PVs
As study duration increased, reporting of enrolment PVs
increased (PLR chi-square < 0.0001, OR = 1.053, 95% CI
1.022 to 1.085) and studies reporting any form of man-
agement structure were more likely to report enrolment
PVs (PLR chi-square = 0.0221, 26/42 management structure
not reported vs. 16/17 basic vs 16/21 more detailed).
Studies that presented ITT results were less likely to
report enrolment PVs (PExact = 0.0313 8/57 vs 9/23) and
there was a trend for studies that reported details of the
generation of randomisation sequence to be less likely
to report enrolment PVs (PExact = 0.0903, 13/71 vs 4/9)
Randomisation PVs
As number of sites increased, a study was more likely to
report randomisation PVs (PLR chi-square = 0.0662, OR =
1.004, 95% CI 1.000 to 1.008) and industry funded trials
were more likely to report randomisation PVs (PExact =
0.0263, 5/21 Industry vs 3/59).
Study Intervention PVs
There was a significant difference (P LR chi-square =
0.0330) in study intervention PV reporting between the
major journals (7/20 BMJ vs. 4/20 JAMA vs. 11/20 Lan-
cet vs. 12/20 NEJM).
As study duration increased, study intervention PV
reporting became more likely (PLR chi-square =0 . 0 5 0 0 ,O R
= 1.021 per month, 95% CI 1.000 to 1.042) and studies
reporting any form of management structure were more
likely to report study intervention PVs (PLR chi-square =
0.0500, 12/42 management structure not reported vs. 11/
17 basic reporting vs 11/21 detailed reporting). Study
intervention PV reporting also became more likely as
number of study sites increased (PLR chi-square = 0.0184,
OR = 1.006 per study site, 95% CI 1.001 to 1.020).
Patient Compliance PVs
There were no significant relationships between any trial
characteristics and the reporting of patient compliance PVs.
Data collection PVs
As study duration increased, papers were more likely to
report data collection PVs (PLR chi-square = 0.0524, OR
1.021, 95% CI 1.000 to 1.042) however studies reporting
ITT results were less likely to report data collection PVs
(P Exact = 0.0777, 19/57 ITT vs 13/23 no ITT). Studies
reporting adherence to GCP recommendations were
also less likely to report data collection PVs (P Exact =
0.0712, 0/5 GCP reported vs. 32/75 GCP not reported).
Discussion
We conducted a comprehensive review of 80 clinical
trials published in four major medical journals in order
Table 2 Characteristics of included trials
Trial Characteristics Percent (number) of
Trials
Study Type
Individual patient RCT 76.25% (61/80)
Factorial RCT 6.25% (5/80)
Cluster RCT 17.5% (14/80)
Number of study arms
Two 83.75% (67/80)
Three 7.5% (6/80)
Four 8.75% (7/80)
Patient Population
Adults 91.25% (73/80)
Children 6.25% (5/80)
Infants 1.25% (1/80)
Mixed (Adults & Children) 1.25% (1/80)
Study Intervention
Drug 46.25% (37/80)
Surgery 8.75% (7/80)
Education 10.0% (8/80)
Other 27.5% (22/80)
Procedure 3.75% (3/80)
Weight loss 3.75% (3/80)
Funding Source
Academic 73.75% (59/80)
Industry 26.25% (21/80)
Trial start-up meeting described 8.75% YES (7/80)
Trial run-in phase described 8.75% YES (7/80)
GCP adherence reported 6.25% YES (5/80)
Lead Investigator reports previous research
experience
62.5% YES (50/80)
Trial results
Harm 2.5% (2/80)
Neutral 32.5% (26/80)
Positive 65.0% (52/80)
Management structure
MC, SC & others (explicit structure) 26.25% (21/80)
MC or SC only (basic structure) 21.25% (17/80)
Not reported 52.8% (42/80)
Abbreviations: RCT - Randomised controlled trials; MC - Management
Committee; SC - Steering Committee; GCP - Good Clinical Practice.
Table 3 Risk of bias of included trials
Methodological Characteristics Percent (number)
of Trials
Details regarding generation of the
randomisation sequence
88.75% (71/80)
Reporting of Allocation Concealment
Maintained 52.5% (42/80)
Unclear 45.0% (36/80)
Not maintained 2.5% (2/80)
Use of any type of blinding 58.75% (47/80)
Presentation of results according to ITT 71.25% (57/80)
Loss to follow-up reported by study arm 92.50% (74/80)
Abbreviations: ITT - Intention To Treat.
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describe current practice with regards to the use of
methods for the reduction of PVs and to investigate
relationships between clinical trial characteristics and
PV rates. Overall, we found that PV reporting was poor.
One third of all reviewed trials failed to provide
r e p o r t i n go fa n yt y p e so fP V s .N o n eo ft h er e v i e w e d
trials presented complete reporting for all types of PVs.
We found that larger clinical trials (more patients
enrolled, more study sites, longer duration of recruit-
ment, more complex management structures) were
likely to have more complete reporting of PVs.
PV reporting
The original and revised CONSORT statements recom-
mend that departures from the study protocol should be
reported [11,12]. Reporting of PVs is essential when
establishing the appropriateness of excluding patients
from a modified intention to treat analysis or an efficacy
subset (per-protocol) analysis [13,14]. Because excessive
PVs have been linked to patient harms [2], which may
dilute the benefits attributable to a truly effective treat-
ment leading to false negative clinical trials results [4],
reporting of protocol errors may also be essential for
the interpretation of negative trial results. Furthermore,
full reporting of PVs is vital to the design of post-
approval safety assessments of new interventions [15].
Despite the plethora of reasons to motivate authors to
report these important measures of good study conduct,
we found reporting of PVs was uncommon.
PV frequency
Patient compliance PVs were the most commonly
reported type of PV and were documented explicitly in
48% of trials. The next most commonly reported were
study intervention PVs (21%), data collection PVs (21%),
enrolment PVs (12%) and technical randomisation PVs
(9%). Estimates of within-trial PV rates obtained from
this review may be biased due to poor reporting
because, as with other aspects of trial conduct, an
absence of PV reporting could not be assumed to infer
no PVs were experienced [16].
Of the 54 clinical trials that did provide explicit
reporting of PV rates, 29% (16/54) reported a PV rate
greater than the 10% threshold defined as excessive by
Pocock [3]. Even in the face of incomplete reporting,
this finding suggests there is room for improvement. It
is likely that a PV rate below 10% could be achieved in
each of these 16 trials if conduct was improved.
Preventing PVs
In order to improve trial conduct, PVs need to be iden-
tified during a clinical trial such that they can be studied
and unnecessary errors can be prevented from occurring
Table 4 Protocol violation reporting and protocol violation frequency.
Protocol Violation Type Percent (number) of trials Proportion of Enrolled Participants with PVs
Median (range)
Calculated from trials with Explicit Reporting
Enrolment PVs
Explicit reporting 12.5% (10/80) 0.8% (1.6% to 9.1%)
Incomplete reporting 8.8% (7/80)
Absent 78.8% (63/80)
Randomisation PVs
Explicit reporting 8.8% (7/80) 0.7% (0.04% to 7.7%)
Incomplete reporting 1.3% (1/80)
Absent 90.0% (72/80)
Study Intervention PVs
Explicit reporting 21.2% (17/80) 1.3% (0% to 13.2%)
Incomplete reporting 21.2% (17/80)
Absent 57.5% (46/80)
Patient compliance PVs
Explicit reporting 47.5% (38/80) 7% (0.2% to 87%)
Incomplete reporting 25.0% (20/80)
Absent 27.5% (22/80)
Data Collection PVs
Explicit reporting 21.3% (17/80) 1.7% (0.0% to 16.1%)
Incomplete reporting 18.8% (15/80)
Absent 60.0% (48/80)
Abbreviations: PV - protocol violations.
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the conduct of a multi-centre trial, the trial’s clinical
coordinating centre (CCC) may provide immediate non-
punitive positive feedback and education to all study
sites to minimise the chances of the same PV occurring
again [6]. None of the reviewed clinical trials explicitly
reported how PVs were studied and prevented during
trial conduct however seven of the reviewed trials did
report use of a run-in phase.
Prior to recruitment into a trial, a run-in phase may
be conducted to identify noncompliant participants and
exclude them from subsequent study enrolment [17].
During a run-in phase, potential participants are given a
test exercise to complete, such as taking 10 days of pla-
cebo medication. Patients are graded on their perfor-
m a n c eo ft h i st e s te x e r c i s ea n do n l yp a t i e n t sw h oa r e
considered to be compliant w i t ht h ee x e r c i s ea r e
enrolled and randomised into the trial [17].
Furthermore, if other processes and procedures are
simulated during a run-in phase, other types of PVs can
be minimized [6].
By preventing enrolment of the least compliant
patients, it is accepted that a successful run-in phase
can increase the overall power of a study however, com-
pared to results that would have been observed without
a run-in phase, the reported results may overestimate
the benefits and underestimate the risks of treatment,
underestimate the number needed to treat, and yield a
smaller P-value [17]. These considerations must be
balanced against the desire to minimise false negative
results by enrolling only those patients who will be com-
pliant with the study intervention.
Factors related to improved reporting
To the best of our knowledge, our investigation of trial
characteristics associated with PV reporting was the first
time such a question has been addressed. Our initial
intent was to conduct an investigation into trial charac-
teristics associated with PV rates, however with such
poor reporting of PVs, we were not able to conduct this
analysis. Even with the best reported type of PV (patient
compliance), up to 50% of trials failed to report a rate.
With a best case scenario of 50% missing data, we were
concerned that estimates of PV rates were open to sig-
nificant potential biases and that any analysis of trial
characteristics associated with PV rates would be under-
powered and of questionable veracity. We therefore
focused our analysis on an investigation of trial charac-
teristics and PV reporting (reported Yes or No).
In general, our analysis indicated that trials with char-
acteristics common to ‘larger’ studies (more patients,
more sites, longer duration, more complex management
structure) were more likely to report PVs. It is possible
that larger studies are more complex to coordinate [18]
and therefore may have more PVs which leads to more
frequent reporting of PVs. It is also possible however,
that the improved management structures associated
with increasing trial size facilitates the recording and
reporting of PVs, regardless of PV rate. We strongly
recommend more research into this issue however
reporting of PV rates must be improved first.
Finally, it is important to acknowledge that we did
identify a significant difference in study intervention PV
reporting between journals. Inspection of the two jour-
nals with the lowest intervention PV reporting (BMJ,
JAMA) revealed that they tended to publish smaller trials
(shorter duration, fewer study sites) that were less likely
to report any form of management structure. It is possi-
ble the difference in intervention PV reporting observed
between journals is attributable to differences in trial
characteristics as opposed to journal policies. Future stu-
dies are needed to investigate this finding in more detail.
Recommendations
Whilst the CONSORT statement does recommend
reporting of PVs [11,12] the format does not place a
heavy emphasis on this issue. We believe the CON-
SORT statement should highlight the importance of
PVs by making reporting requirements more explicit. It
is accepted in the literature that authors and journal
editors do respond to CONSORT recommendations by
improving reporting of trial features [19,20]. Modifica-
tions to the CONSORT statement are the first step
towards improved reporting of PVs.
Clinical trialists should embrace Wolf’s definition of a
protocol violation [10] because it incorporates the con-
cept of causality which allows a trialist to identify PVs
that are preventable. Application of this definition to
identify errors in conduct that occur early during a trial
may allow future errors to be avoided, thus reducing
overall PV rates.
We recommend that journal editors should require
full reporting of PVs. Full reporting will enable future
research projects to identify relationships between PVs
and study characteristics and to examine any influence
of excessive PVs on study results. Research in this field
may lead to improvements in the overall conduct of
future clinical trials.
Strengths and Weaknesses
To the best of our knowledge, this study is the first
review to describe PV reporting in a sample of clinical
trials which were conducted across a broad range of
medical specialties and published in four major general
medical journals. Others have based methodological
reviews on these four major journals [21-24] however
clinical trials published in these journals may not be
representative of all published trials.
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clinical trials published in The Lancet, NEJM, JAMA
and the BMJ are known to be larger (more patients,
more study sites, longer duration of recruitment) and
are more likely to be regarded as low risk of bias due to
improved reporting of methodological details [25].
Because the findings of this report are based on a very
select type of atypical trial, it is possible the current
results do not generalise to trials published in other
journals. Given we found poor reporting of PVs in these
major general medical journals, there is no reason to
suspect that PV reporting is better in sub-specialist jour-
nals however, more research is required to address this
issue.
The published literature provides many working defi-
nitions of a protocol violation or protocol deviation. We
chose the definition by Wolf [10] because it encom-
passes the concept of causality which helps identify
study errors that are preventable [3]. Wolf defines a PV
as a preventable error in study conduct, whereas a pro-
tocol deviation is unpreventable (e.g. study drug must
be stopped due to safety etc.). Furthermore, we classified
PVs into five main types based on the study process
involved and source of the error. We find this classifica-
tion useful because it aids in the identification of an
appropriate response to the error.
Another limitation of this study is the relatively small
sample size of 80 papers. It is possible that we failed to
find some significant associations between trial charac-
teristics and PV reporting due to sub-optimal power.
Although we found interesting associations, larger stu-
dies may be required to investigate PVs in more detail.
Conclusions
We undertook this comprehensive review to gain a bet-
ter understanding of reported PV rates, to describe cur-
rent practice with regards to the use of methods for the
reduction of PVs and to investigate relationships
between clinical trial characteristics and PV rates.
Overall, we found that reporting of PVs was poor
however larger trials were more likely to report PVs.
Furthermore, few clinical trials documented methods
used to prevent or minimise PVs.
Preventable errors in study conduct may lead to
avoidable patient harm and may result in false negative
trial results. As a first step towards improving our
understanding of the influence of PVs, reporting must
be improved. We recommend changes to the CON-
SORT statement that make reporting requirements for
PVs more explicit. Once reporting is improved, more
research may reveal how to prevent and minimize PVs.
For example, a severity grading system for PVs may
allow clinical trialists to focus on preventing the most
important types of PV thereby reducing avoidable
patient harm and removing bias from the results of our
clinical trials.
Author details
EAS is a Senior Research Fellow at the Northern Clini-
cal School Intensive Care Research Unit, University of
Sydney, Sydney, Australia. GSD is the Head of the
Northern Clinical School Intensive Care Research Unit,
University of Sydney, Sydney, Australia and Associate
Professor in Intensive Care, at the Faculty of Medicine,
University of Sydney, Sydney, Australia.
List of Abbreviations Used
95% CI: 95% Confidence Interval; OR: Odds Ratio; PV: Protocol Violation; RCT:
Randomised Controlled Trial; CCC: Clinical Coordinating Centre; ITT: Intention
To Treat.
Acknowledgements
Funding
Australian National Health and Medical Research Council project grants
632614 and 632615.
Author details
1Northern Clinical School Intensive Care Research Unit, University of Sydney,
Sydney, Australia.
2Faculty of Medicine, University of Sydney, Sydney,
Australia.
Authors’ contributions
EAS and GSD conceived and designed the study, managed the project,
conducted the statistical analysis, interpreted the results and drafted the
manuscript. GSD had full access to all of the data in the study and takes full
responsibility for the integrity of the data and the accuracy of the data
analysis.
Competing interests
The authors declare that they have no competing interests.
Received: 11 July 2011 Accepted: 28 September 2011
Published: 28 September 2011
References
1. DiFrancesco R, Rosenkranz SL, Craft J, Morse GD: Tutorial reduces protocol
deviations in multicenter ACTG trials with pharmacology endpoints. HIV
Clinical Trials 2006, 7:203-209.
2. Macias WL, Vallet B, Bernard GR, Vincent JL, Laterre PF, Nelson DR,
Derchak A, Dhainaut JF: Sources of variability on the estimate of
treatment effect in the PROWESS trial: implications for the design and
conduct of future studies in severe sepsis. Crit Care Med 2004,
32:2385-2391.
3. Pocock SJ: Protocol Deviations. In Clinical Trials: A Practical Approach.
Edited by: Pocock SJ. New York: John Wiley 1983:176-186.
4. Sprung CL, Finch RG, Thijs LG, Glauser MP: International sepsis trial
(INTERSEPT): role and impact of a clinical evaluation committee. Crit Care
Med 1996, 24:1441-1447.
5. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of
recombinant human activated protein C for severe sepsis. N Engl J Med
2001, 344:699-709.
6. Simpson F, Sweetman EA, Doig GS: A systematic review of techniques
and interventions for improving adherence to inclusion and exclusion
criteria during enrolment into randomised controlled trials. Trials 2010,
11:11-17.
7. Doig GS, Simpson F, Sweetman EA: Use of a formal study run-in phase to
reduce recruitment errors in a multicentre randomised controlled trial: is
quality better than quantity?[Abstract]. Asia Pacific Critical Care Congress -
Sydney, Congress Guide: 30 October - 2nd November 2008 Sydney; 2008,
79-80.
Sweetman and Doig Trials 2011, 12:214
http://www.trialsjournal.com/content/12/1/214
Page 7 of 88. Haynes RB, McKibbon KA, Wilczynski NL, Walter SD, Werre SR: Optimal
search strategies for retrieving scientifically strong studies of treatment
from Medline: analytical survey. BMJ 2005, 330:1179-1185.
9. Higgins JPT, Green S: Assessing risk of bias in included studies. In
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. Edited by: Higgins JPT, Altman DJ, Sterne J. The
Cochrane Collaboration; 2011:8.1-8.17 [http://www.cochrane-handbook.org].
10. Wolf GT, Makuch RW: Editorial: a classification system for protocol
deviations in clinical trials. Cancer Clin Trials 1980, 3:101-103.
11. Schulz KF, Altman DG, Moher D, the CONSORT Group: CONSORT 2010
Statement: Updated guidelines for reporting parallel group randomised
trials. J Clin Epid 2010, 63:834-840.
12. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ,
Elbourne D, Egger M, Alman DG: CONSORT 2010 Explanation and
Elaboration: Updated guidelines for reporting parallel group randomised
trials. J Clin Epidemiol 2010, 63:e1-37.
13. Fergusson D, Aaron SD, Guyatt G, Hebert P: Post-randomisation
exclusions: the intention to treat principle and excluding patients from
analysis. BMJ 2002, 325:652-654.
14. Lachin JL: Statistical considerations in the intent-to-treat principle.
Control Clin Trials 2000, 21:526.
15. Graham GD: Tissue plasminogen activator for acute ischemic stroke in
clinical practice: a meta-analysis of safety data. Stroke 2003, 34:2847-2850.
16. Schulz KF, Grimes DA: Sample size slippages in randomised trials:
exclusions and the lost and wayward. Lancet 2002, 359:781-785.
17. Pablos-Mendez A, Barr RG, Shea S: Run-in periods in randomized trials:
implications for the application of results in clinical practice. JAMA 1998,
279:222-225.
18. Meinert CL: Organization of multicenter clinical trials. Control Clin Trials
1981, 1:305-312.
19. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does
the CONSORT checklist improve the quality of reports of randomised
controlled trials? A systematic review. Med J Aust 2006, 185:263-267.
20. Doig GS, Simpson F, Delaney A: A review of the true methodological
quality of nutritional support trials conducted in the critically ill: time for
improvement. Anesth Analg 2005, 100:527-533.
21. Hollis S, Campbell F: What is meant by intention to treat analysis? Survey
of published randomised controlled trials. BMJ 1999, 319:670-674.
22. Wood AM, White IR, Thompson SG: Are missing outcome data adequately
handled? A review of published randomized controlled trials in major
medical journals. Clin Trials 2004, 1:368-376.
23. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM: Adequacy and
reporting of allocation concealment: review of recent trials published in
four general medical journals. BMJ 2005, 330:1057-1058.
24. Pocock SJ, Assmann SE, Enos LE, Kasten LE: Subgroup analysis, covariate
adjustment and baseline comparisons in clinical trial reporting: current
practice and problems. Stat Med 2002, 21:2917-2930.
25. Chan AW, Altman DG: Epidemiology and reporting of randomised trials
published in PubMed journals. Lancet 2005, 365:1159-1162.
doi:10.1186/1745-6215-12-214
Cite this article as: Sweetman and Doig: Failure to report protocol
violations in clinical trials: a threat to internal validity? Trials 2011 12:214.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sweetman and Doig Trials 2011, 12:214
http://www.trialsjournal.com/content/12/1/214
Page 8 of 8